Abstract
Glioblastoma (GBM) remains one of the most challenging brain tumors to treat, with limited response to current therapies. This thesis investigates personalized oncolytic virotherapy as a novel approach to treat GBM, focusing on identifying biomarkers for response prediction, exploring ex vivo models for patient-specific outcomes. Through immune profiling and molecular analyses, we assess the role of tumor heterogeneity and the immune microenvironment in modulating OV efficacy.
Key molecular markers were identified that predict tumor sensitivity to OVs such as Delta24-RGD, R124, NDV, and rQNestin34.5v1. Notably, our findings also reveal the heterogeneous responses of pediatric high-grade gliomas, atypical teratoid/rhabdoid tumors, and ependymomas to virotherapy, underscoring the need for tailored approaches in pediatric oncology. Additionally, an autologous ex vivo model was developed to evaluate patient-specific immune responses, enabling more accurate predictions of viro-immunotherapy outcomes.
This work highlights the potential of personalized virotherapy for glioblastoma and pediatric brain tumors by integrating biomarker-driven strategies with ex vivo immune models. These findings lay the groundwork for incorporating oncolytic viruses into individualized treatment protocols that account for the unique molecular and immune profiles of each patient, ultimately improving therapeutic outcomes.
Key molecular markers were identified that predict tumor sensitivity to OVs such as Delta24-RGD, R124, NDV, and rQNestin34.5v1. Notably, our findings also reveal the heterogeneous responses of pediatric high-grade gliomas, atypical teratoid/rhabdoid tumors, and ependymomas to virotherapy, underscoring the need for tailored approaches in pediatric oncology. Additionally, an autologous ex vivo model was developed to evaluate patient-specific immune responses, enabling more accurate predictions of viro-immunotherapy outcomes.
This work highlights the potential of personalized virotherapy for glioblastoma and pediatric brain tumors by integrating biomarker-driven strategies with ex vivo immune models. These findings lay the groundwork for incorporating oncolytic viruses into individualized treatment protocols that account for the unique molecular and immune profiles of each patient, ultimately improving therapeutic outcomes.
Original language | English |
---|---|
Awarding Institution |
|
Supervisors/Advisors |
|
Award date | 5 Nov 2024 |
Place of Publication | Rotterdam |
Print ISBNs | 978-94-6510-121-7 |
Publication status | Published - 5 Nov 2024 |